The FDA approved intravenous immunoglobulins (IVIG; Octagam 10%) for treating adults with dermatomyositis, a rare chronic autoimmune disease, drugmaker Octapharma announced on Tuesday. Support for the ...
This retrospective chart review studied patients with PM or DM in France. Esophageal involvement in these patients was diagnosed by 3 variables: clinical manifestations of reflux, dysphagia, coughing ...
Treatment with intravenous immunoglobulins (IVIG) for dermatomyositis was effective in a pivotal phase III randomized trial, a researcher reported. At week 16, 78.72% of patients receiving IVIG were ...
– RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. patients with no approved treatments other than monthly ...
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results